Nonfunctional adrenocortical carcinoma initially presenting as retroperitoneal hemorrhage

Shinichiro Kashiwagi1*, Ryosuke Amano1, Naoyoshi Onoda1, Satoru Noda1, Keiichiro Hirata1, Yuka Asano1, Kento Kurata1, Koutaro Miura1, Sadaaki Yamazoe1, Kenjiro Kimura1, Masahiko Ohsawa2, Seiichi Kitagawa3, and Kosei Hirakawa1

Abstract

Background: Acute adrenal hemorrhage is an uncommon entity. Although trauma is the most common cause of adrenal hemorrhage, non-traumatic etiologies have also been reported. We report an unusual case of a spontaneously ruptured adrenocortical carcinoma that initially presented as a critical massive retroperitoneal hemorrhage. The case was treated successfully using a combination of emergency interventional radiology and elective surgery.

Case presentation: A 47-year-old woman was transported to our hospital because of the sudden onset of severe pain in her left lower back. The shadow of a tumor-like soft mass accompanied by bleeding was observed in the upper pole of the left kidney, together with vascular leakage from the middle suprarenal artery on computed tomography. Transcatheter embolization of the left middle adrenal artery was administered based on a diagnosis of acute adrenal hemorrhage. Further observation indicated that the bleeding was caused by rupture of an adrenocortical carcinoma. Left adrenalectomy was subsequently carried out via laparotomy.

Conclusions: We experienced an unusual case of acute massive adrenal hemorrhage caused by the rupture of a non-functional adrenocortical carcinoma, which was treated successfully by ambulatory transcatheter embolization therapy and elective surgery.

Keywords: Adrenocortical carcinoma, Retroperitoneal hemorrhage, Mitotane, Interventional radiology, Surgery

Background

Adrenocortical carcinoma is an uncommon disease, accounting for approximately 0.02% of all malignant tumors [1-3]. This tumor often exhibits endocrine activity, commonly in association with Cushing’s syndrome, because of excessive secretion of cortisol from the tumor cells. Nevertheless, non-functional tumors are also occasionally detected [1-3]. About 30% of adrenocortical carcinomas are diagnosed incidentally during imaging procedures for unrelated medical issues [4]. However, the asymptomatic nature of the tumor means that diagnosis is often delayed, and such lesions are therefore usually found only after the disease has progressed to an advanced stage, resulting in a poor outcome. Acute adrenal hemorrhage mostly occurs within adrenal tumors and the adrenal glands, often resulting in the formation of massive hematomas extending into the retroperitoneum, in association with urgent symptoms such as lower back pain, acute adrenal crisis, circulatory failure, and shock [5,6]. Anticoagulant therapy is a potential predisposing factor, but was not relevant to the present case [7]. In addition, we can leave when both adrenal hemorrhage compares it if unilat-

Case presentation

A 47-year-old woman was transported to our hospital because of the sudden onset of severe pain in her left lower back. She was alert and conscious, with a blood pressure of 165/95 mmHg, pulse of 77 beats/minute,
and oxygen saturation of 95%. She appeared to be in distress and complained of sharp spontaneous pain in her lower left back. She was 162.0 cm tall and weighed 84.5 kg. There were no physical features suggestive of Cushing’s syndrome. The patient had been healthy with no particular past medical history or familial disease. Her white blood cell count was 11,800/μL and her hemoglobin level was 8.8 g/dL. Other than these findings, biochemical tests and urinalysis on admission demonstrated no particular abnormalities (Table 1). Emergency contrast-enhanced computed tomography (CT) of the abdomen revealed a tumor-like soft mass accompanied by massive bleeding in the retroperitoneum on the upper pole of the left kidney, in addition to vascular leakage from the middle suprarenal artery (Figure 1a, b). Immediately after obtaining the results of the CT scan, transcatheter embolization therapy of the left middle adrenal artery was performed based on a diagnosis of

**Table 1 Laboratory data on admission**

| Blood count | Tumor marker |
|-------------|--------------|
| WBC 11,800/μL | CEA 1.6 ng/ml |
| RBC 303 x 10⁶/μL | CA19-9 18 U/ml |
| Hb 8.8 g/dL | |
| Hct 26.6% | |
| PLT 21.8 x 10⁶/μL | |

| Blood chemistry | Endocrinology (normal range) |
|-----------------|-----------------------------|
| TP 7.1 g/dL | Vanillymandelic acid 8.0 ng/ml (3.3 ~ 8.6) |
| Alb 4.1 g/dL | Adrenaline <0.01 ng/ml (0.00 ~ 0.17) |
| AST 13 IU/l | Nor-Adrenaline 0.42 ng/ml (0.15 ~ 0.57) |
| ALT 13 IU/l | Dopamine <0.02 ng/ml (0.00 ~ 0.03) |
| ALP 262 IU/l | Cortisol 9.2 μg/dl (4.0 ~ 19.3) |
| LDH 137 IU/l | ACTH 46.9 pg/ml (7.2 ~ 63.3) |
| T-Bil 0.5 mg/dl | DHEA-S 225 μg/dl (33 ~ 262) |
| BUN 9 mg/dl | |

| Urinary Cathecolamine (normal range) |
|-------------------------------------|
| Cre 0.88 mg/dl | Vanillymandelic acid 3.5 mg/day (1.4 ~ 4.9) |
| Na 142 mEq/l | Adrenaline 12.1 μg/day (1.0 ~ 23.0) |
| K 4.0 mEq/l | Nor-Adrenaline 94.2 μg/day (29 ~ 120) |
| Cl 106 mEq/l | Dopamine 260 μg/day (100 ~ 1000) |
| Ca 8.9 mEq/l | Metanephrine 0.11 mg/day (0.05 ~ 0.20) |
| P 3.1 mEq/l | Normetanephrine 0.19 mg/day (0.1 ~ 0.28) |

**Figure 1** Contrast-enhanced CT findings. a. Emergency contrast-enhanced CT of the abdomen revealed a tumor-like soft mass accompanied by massive bleeding in the retroperitoneum (Transverse plane). b. Coronal plane.
acute adrenal hemorrhage, possibly from a ruptured adrenal tumor (Figure 2a, b). The patient’s condition subsequently stabilized and a detailed investigation of the cause of the adrenal hemorrhage was initiated. Magnetic resonance imaging (MRI) revealed a hematoma expanded within the Gerota’s fascia, and a round tumor was detected in addition to the hematoma, with a rich vasculature and possible necrotic area (Figure 3a, b). No liver nodules or swelling of the retroperitoneal lymph nodes suggestive of metastasis were observed. Endocrine function of the adrenal gland appeared normal. The above findings indicated a ruptured non-functional adrenocortical tumor. Imaging confirmed the absence of metastatic lesions, and the tumor was removed by elective laparotomy surgery 2 months later. Regarding the surgical findings, no hemorrhage or abnormal adhesion was observed in the abdominal cavity. A soft elastic tumor measuring 10 cm was palpable in the retroperitoneum at the inferior border of the pancreatic body. Although it adhered closely to the surrounding retroperitoneal fatty tissue, the tumor was removed en bloc by partially excising Gerota’s fascia, without leaving any remnants. No invasion into the surrounding organs, lymph node metastasis, or liver metastasis was observed. The operative time was 229 min, and the surgical blood loss was approximately 500 mL. The patient recovered uneventfully. The tumor measured 13.5 × 8.6 × 4.2 cm and weighed 380 g. The cut surface indicated a yellowish solid tumor, with areas of bleeding accompanied by necrosis in a branched pattern (Figure 4a, b). The normal adrenal gland could not be identified visually. Histopathological examination revealed proliferated tumor cells with an atypical morphology, with an eosinophilic or clear cytoplasm and large nucleus containing a distinct nucleolus (Figure 5a, b). Nuclear atypia and abundant nuclear mitotic images were observed (≥11 per 50 high-power fields (HPF)). A wide focus of necrosis was also noted, although there was no apparent invasion outside the capsule. The final diagnosis was a ruptured, non-functioning left adrenocortical carcinoma, pT2N0M0, stage II. Mitotane
administration for 2 years was planned as adjuvant therapy. The patient was alive at 6 months after surgery, with no serious adverse events or relapse.

**Discussion**

Adrenocortical carcinoma is an uncommon disease found in 0.5–2 per million people, accounting for only 0.02% of all malignant tumors [1-3]. Approximately 40% of adrenocortical carcinomas have been reported to be non-functional [1-3]. In contrast, Cushing’s syndrome is often present in cases of functioning tumors [1], with dehydroepiandrosterone sulfate as a tumor marker. The prognosis of patients with adrenocortical carcinoma is poor, with a 5-year survival rate of 16–35% [8], largely attributable to the fact that approximately 80% of cases are discovered at an advanced stage [9]. In the present case, however, although the tumor was large, no extracapsular invasion or metastasis had occurred and complete resection was accomplished successfully.

CT and MRI are useful modalities for diagnosing adrenocortical carcinoma [10-12]. Tumors ≥5 cm are highly likely to be malignant, and non-uniform imaging effects/necrosis in the center accompanied by calcification have been reported to be a common finding of malignant tumors [10]. Typical adrenocortical cancer presents with low signals on T1 intensity MRI images and non-uniform high signals on T2 intensity images [11,12]. The diagnosis of non-functional adrenocortical carcinomas using adrenal cortex scintigraphy is generally regarded as difficult. However, Weiss criteria are often used to differentiate between malignant adrenocortical tumors and benign tumors pathologically [13,14]. Nine criteria are assessed, including a high nuclear grade, >5 mitoses per 50 HPF, atypical mitotic figures, <25% clear cells, a diffuse architecture, necrosis, venous invasion, sinusoidal invasion, and capsular invasion. The diagnosis in the present case was made based on four criteria: nuclear grade, mitotic index, diffuse architecture, and necrosis.

**Figure 4** Resected specimen. a. The tumor measured in 13.5 × 8.6 × 4.2 cm and weighed 380 g. b. The cut surface was yellow and solid, and areas of bleeding accompanied by necrosis.

**Figure 5** Histopathological findings. a. Histopathological findings of solidly proliferating tumor cells showing an atypical morphology with an eosinophilic or clear cytoplasm and large nucleus containing a distinct nucleolus (Nuclear atypia: Fuhrman criteria Grade III). b. Arrow: atypical mitotic figures. (Hematoxylin and eosin staining × 400).
Surgical resection is the treatment of choice in patients with adrenocortical carcinoma, and survival can be prolonged significantly among patients able to undergo radical excision [1,14]. The steroidogenesis repressor mitotane is often used in cases of advanced disease, or as postoperative adjuvant therapy. Previous reports also found that the administration of postoperative adjuvant therapy following radical surgery prolonged relapse-free survival [15]. However, no universal consensus has been reached regarding the efficacy of mitotane as adjuvant therapy [4,16,17].

Adrenal hemorrhage is an uncommon entity. Although trauma is the most common cause, non-traumatic etiologies have also been reported. Large and progressively growing tumorous lesions, such as adrenocortical carcinomas, pheochromocytomas, metastatic tumors, and myelolipomas, may carry a risk of tearing or rupture, either alone or in combination with hemorrhagic diathesis, stress, or other idiopathic causes [4,16,17]. Massive adrenal hemorrhage remains rare. With respect to its treatment, follow-up is therefore often sufficient if the patient’s systemic condition is stable and findings for tumorous lesions are negative [17]. However, if the patient’s systemic condition is unstable or bleeding from a tumorous lesion is suspected, as in the current case, adrenalectomy, including the hematoma, is required [17,18]. The effective application of transcatheter embolization therapy has been reported, including in the present case, suggesting its potential value in patients with an unstable systemic condition [19-21].

We experienced an unusual case of acute massive adrenal hemorrhage caused by the rupture of a non-functional adrenocortical carcinoma, which was treated successfully with ambulatory transcatheter embolization therapy and elective surgery.

Conclusions
We experienced an unusual case of acute massive adrenal hemorrhage caused by the rupture of a non-functional adrenocortical carcinoma, which was treated successfully by ambulatory transcatheter embolization therapy and elective surgery.

Consent
Written informed consent was obtained from the patient for publication of this case report, including the associated images.

Abbreviations
CT: computed tomography, MRI: magnetic resonance imaging.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors were involved in the preparation of this manuscript. SKa performed the operation, collected the data, and wrote the manuscript. RA, NO, SN, and KHi performed the operation and designed the study. YA, KKu, and KM summarized the data and revised the manuscript. SY and KKi performed the operation and collected the data. MO, SKi, and KHi made substantial contributions to the study design, performed the operation, and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments
We thank Sayaka Tanaka (Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine) for helpful advice regarding pathological evaluation.

Author details
1 Department of Surgical Oncology, Osaka City University Graduate School of Medicine; 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. 2 Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. 3 Department of Physiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.

Received: 1 April 2014 Accepted: 1 April 2015
Published online: 18 April 2015

References
1. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Gaoli EM, et al. Adrenocortical carcinoma. Endocrine Rev. 2014;35:282–326.
2. Linda NG, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;1695–11.
3. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001;25:914–26.
4. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metabol. 2009;23:273–89.
5. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322:1195–201.
6. Fassnacht M, Allolio B. Epidemiology of adrenocortical carcinoma. In: Hammer G, Else T, editors. Adrenocortical carcinoma. 1st ed. New York, NY: Springer; 2010. p. 23–9.
7. McDonald FD, Myers AR, Pardo R. Adrenal haemorrhage during anticoagulant therapy. JAMA. 1996;198:1052–6.
8. Schlick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719–26.
9. Stojadinovic A, Ghosein RA, Hoos A, Nissan A, Marshall D, Dudas M, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20:941–50.
10. Kawashima A, Sander CM, Fishman EK, Chamsangavej C, Yasumori K, Honda H, et al. Spectrum of CT findings in nonmalignant disease of the adrenal gland. Radiographics. 1998;18:393–412.
11. Kawashima A, Sander CM, Ernst RD, Takahashi N, Roubidoux MA, Goldman SM, et al. Imaging of nontraumatic hemorrhage of the adrenal gland. Radiographics. 1999;19:49–63.
12. Schlund JF, Kenney PJ, Brown ED, Ascher SM, Brown JJ, Semelka RC. Adrenocortical carcinoma: MR imaging appearance with current techniques. J Magn Reson Imaging. 1995;5:171–4.
13. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1994;18:163–9.
14. Weiss LM, Medeiros LJ, Vickery Jr AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13:202–6.
15. Terzolo M, Angeli A, Fassinacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–80.
16. Waehnelt BL, Abbergaria Pereira MA, Medonca BB, Latronico AC, Campos Canedo P, Alves VA, et al. Adreno carcinoma: clinical and laboratory observations. 2000;88:711–36.
17. Fassinacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551–64.
18. Pode D, Caine M. Spontaneous retroperitoneal hemorrhage. J Urol. 1992;147:311–8.
19. Bunuan HD, Alltree M, Merendino KA. Gel foam embolization of a functioning pheochromocytoma. Am J Surg. 1978;136:395–8.
20. Timmis JB, Brown MJ, Allison DJ. Therapeutic embolization of phaeochromocytoma. Br J Radiol. 1981;54:420–2.
21. Horton JA, Hrabovsky E, Klingberg WG, Hostler JA, Jenkins JJ. Therapeutic embolization of a hyperfunctioning pheochromocytoma. AJR Am J Roentgenol. 1983;140:987–8.